Anti-Nectin-4 Exatecan ADC With Stable Release and Lower Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-Nectin-4 antibody drug conjugates (ADCs) face challenges such as undesirable skin toxicity, drug resistance, ocular and peripheral neuropathy, immunogenicity, unstable pharmacokinetics, and inadequate chemical and physical stability, necessitating improved ADCs with enhanced specificity, stability, and potency for effective cancer treatment.
Innovation Solution
Development of a novel anti-Nectin-4 ADC comprising a selective antibody conjugated to exatecan via a linker, utilizing specific heavy and light chain variable regions and modified Fc regions to reduce immunogenicity and enhance stability, with controlled payload release upon cellular internalization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enfortumab vedotin is used as an anti-Nectin-4 ADC, then anti-tumor activity is achieved, but skin toxicity occurs due to non-discriminate binding to skin cells
Solution Approach 1:
The patent applies local quality by modifying the antibody's Fc region to create localized changes in binding properties. The Fc region is engineered with specific mutations (e.g., L234F, L235E, P331S) that alter its interaction with Fc receptors and complement system, thereby changing the local binding characteristics to reduce off-target effects on skin cells while preserving tumor targeting capability
Solution Approach 2:
The patent employs parameter changes by systematically varying the amino acid sequence of the Fc region through multiple mutation combinations. These parameter changes in the Fc region's structure and binding affinity are optimized to achieve the desired balance between tumor targeting specificity and reduced skin cell binding, thereby minimizing skin toxicity
2Duration of action of stationary object
If long-term administration of enfortumab vedotin is performed, then sustained anti-tumor effect is achieved, but drug-resistant cancer occurs
Solution Approach 1:
The patent applies preliminary anti-action by pre-modifying the antibody's Fc region to alter its effector functions before administration. The engineered Fc region with specific mutations is designed to modulate immune system interactions in advance, potentially preventing the development of resistance mechanisms by maintaining effective immune-mediated tumor cell killing throughout prolonged treatment
Solution Approach 2:
The patent employs dynamics by creating an antibody with modified Fc region that can dynamically interact with the immune system. The engineered Fc region allows for adaptable immune system engagement, enabling the ADC to maintain effectiveness against tumor cells over time by modulating immune responses according to the tumor microenvironment conditions
3Stability of the object's composition
If ADC stability is improved for systemic administration, then in vivo stability is enhanced, but payload release upon internalization may be delayed
Solution Approach 1:
The patent applies segmentation by dividing the ADC into distinct functional components with optimized properties: a stable Fc region for systemic circulation, a targeted Fab region for tumor binding, and a cleavable linker for controlled payload release. The Fc region is engineered for stability while the linker portion is designed to be cleavable under specific intracellular conditions, achieving both stability and controlled release
Solution Approach 2:
The patent employs an intermediary approach by using a cleavable linker as a mediator between the stable Fc region and the payload. The linker acts as an intermediate structure that maintains stability during circulation but can be cleaved by specific intracellular enzymes or conditions, thereby facilitating controlled payload release at the target site without compromising overall ADC stability
Data Source
AI summary
The present disclosure provides Nectin-4 antibody drug conjugates (ADCs) comprising exatecan and pharmaceutical compositions thereof, and methods of using the ADCs for the treatment of cancer.